SCHEMBL21055249

SCHEMBL21055249

COc1ccc(O)c(C(F)(F)F)n1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.39
PDE10A Q9Y233 4/20 0.37
KDM4E B2RXH2 2/20 0.37
XBP1 P17861 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PDE2A O00408 3/20 0.36
HTT P42858 2/20 0.36
HSD17B10 Q99714 1/20 0.36
NNMT P40261 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11955243 0.82 ALOX15 (0.39) POLBTDP1KMT2AHTTHSD17B10
SCHEMBL21859884 0.78 HTT (0.44) TSHRPDE10AKDM4EXBP1NPSR1
SCHEMBL29957707 0.78 TSHR (0.37) TSHRPDE10AKDM4EXBP1NPSR1
SCHEMBL21055330 0.78 TSHR (0.37) TSHRPDE10AKDM4EXBP1NPSR1
SCHEMBL3668196 0.77 TSHR (0.42) TSHRPDE10AKDM4EXBP1NPSR1
SCHEMBL30508619 0.77 TSHR (0.42) TSHRPDE10AKDM4EXBP1NPSR1
SCHEMBL5391265 0.77 TSHR (0.39) TSHRPDE10AKDM4EXBP1NPSR1
SCHEMBL21859496 0.76 TSHR (0.38) TSHRPDE10AKDM4EXBP1NPSR1
SCHEMBL21859512 0.74 PDE10A (0.41) TSHRPDE10AKDM4EXBP1NPSR1
SCHEMBL21725475 0.74 TSHR (0.37) TSHRPDE10AKDM4EXBP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases ARRAY BIOPHARMA INC (US) 2022-02-15 US disclosed
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases ARRAY BIOPHARMA INC (US) 2022-02-15 US disclosed
WO-2019113190-A1 BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES ARRAY BIOPHARMA INC. (US) 2019-06-13 WO disclosed
WO-2019113190-A1 BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES ARRAY BIOPHARMA INC. (US) 2019-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases MAP3K1, MAP3K3, MAP3K2 TSHR 724/4885PDE10A 1944/4885KDM4E 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.